Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $39.55 and traded as high as $44.96. Omnicell shares last traded at $44.50, with a volume of 259,977 shares trading hands.
Analyst Ratings Changes
A number of equities analysts have commented on OMCL shares. Benchmark reiterated a "buy" rating and issued a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Bank of America restated a "neutral" rating and set a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Wells Fargo & Company upped their target price on Omnicell from $30.00 to $41.00 and gave the company an "equal weight" rating in a research report on Monday, October 14th. JPMorgan Chase & Co. raised their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Finally, Craig Hallum increased their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Omnicell has a consensus rating of "Hold" and a consensus price target of $52.00.
View Our Latest Stock Report on Omnicell
Omnicell Stock Down 2.9 %
The business has a 50-day simple moving average of $45.58 and a two-hundred day simple moving average of $39.65. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -110.77, a P/E/G ratio of 34.96 and a beta of 0.78.
Insider Activity
In other news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.64% of the company's stock.
Hedge Funds Weigh In On Omnicell
Several hedge funds have recently bought and sold shares of the business. Pacer Advisors Inc. raised its position in shares of Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company's stock valued at $56,047,000 after purchasing an additional 508,789 shares during the period. Dimensional Fund Advisors LP grew its stake in Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company's stock valued at $31,955,000 after buying an additional 3,570 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company's stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the period. ArrowMark Colorado Holdings LLC lifted its position in Omnicell by 27.1% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company's stock worth $49,742,000 after acquiring an additional 243,353 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock valued at $48,176,000 after acquiring an additional 2,877 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.
Omnicell Company Profile
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Articles
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
